A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetic and safety and tolerability
profile of TAK-079 following a single intravenous (IV) infusion or subcutaneous (SC)
administration at escalating dose levels in healthy participants.